About: Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Sector: Healthcare
Industry: Biotechnology
Status: Delisted — removed_from_provider. This asset is no longer trading; historical data is shown.
QLGNNASDAQQualigen Therapeutics Inc
Qualigen Therapeutics Inc share price
QLGN price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
QLGN price performance
QLGN Market Signals